共 50 条
- [1] ROLAPITANT, A NOVEL NK-1 RECEPTOR ANTAGONIST (NK1-RA), PHASE 3 TRIAL RESULTS IN THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN SUBJECTS RECEIVING HIGHLY OR MODERATELY EMETOGENIC CHEMOTHERAPY (HEC AND MEC).ONCOLOGY NURSING FORUM, 2015, 42 (02) : E222 - E223Clark-Snow, RebeccaNagy, CindyArora, SujataPoma, AllenNavari, Rudolph
- [2] Phase 3 trial results for rolapitant, a novel NK-1 receptor antagonist, in the prevention of chemotherapy-induced nausea and vomiting (CINV) in subjects receiving highly emetogenic chemotherapy (HEC).JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)Rapoport, Bernardo LeonPoma, AllenHedley, Mary LynneMartell, Robert E.Navari, Rudolph M.
- [3] Safety of rolapitant, a novel NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic chemotherapy (MEC or HEC)JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)Urban, LaszloPoma, AllenDardeno, Michelle MottaMartell, Robert E.
- [5] Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in moderately emetogenic therapy (MEC)JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Hesketh, Paul JosephSchwartzberg, Lee StevenModiano, Manuel R.Arora, SujataPoma, AllenSchnadig, Ian D.
- [6] Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC)Supportive Care in Cancer, 2015, 23 : 3281 - 3288Bernardo RapoportDaniel ChuaAllen PomaSujata AroraYan WangLuis Enrique Fein
- [7] Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC)SUPPORTIVE CARE IN CANCER, 2015, 23 (11) : 3281 - 3288Rapoport, BernardoChua, DanielPoma, AllenArora, SujataWang, YanFein, Luis Enrique
- [8] Phase II clinical trial overview of the novel neurokinin-1 (NK-1) antagonist, casopitant, for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately and highly emetogenic chemotherapyONCOLOGY NURSING FORUM, 2008, 35 (03) : 557 - 557Rogers, MiriamPence, ChristineRusso, Mark
- [9] Phase III results for the novel neurokinin-1 (NK-1) receptor antagonist, casopitant: 3-day IV/oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving moderately emetogenic chemotherapy (MEC)JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)Aziz, Z.Arpornwirat, W.Herrstedt, J.Camlett, I.Piontek, T.Ranganathan, S.Schnyder, J.Bandekar, R. R.Levin, J.Shaharyar, A.
- [10] Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of highly or moderately emetogenic chemotherapy (HEC, MEC).JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (29)Rapoport, Bernardo LeonSchwartzberg, Lee StevenChasen, Martin RobertPowers, DanielArora, SujataNavari, Rudolph M.Schnadig, Ian D.